Literature DB >> 22209316

TNFα: activator or inhibitor of regulatory T cells?

Jérôme Biton1, Marie-Christophe Boissier, Natacha Bessis.   

Abstract

TNFα is a cytokine that is central to the pathogenesis of several autoimmune diseases. More specifically, the deleterious effects of TNFα in rheumatoid arthritis (RA) are well established. The proinflammatory influence of TNFα in RA is related both to direct effects mediated by the induction of other proinflammatory cytokines, metalloproteinases, and free radicals; and to modulation of the regulatory T cells (Tregs). Furthermore, the TNFα antagonists used to treat RA can induce the emergence of a distinctive Treg subpopulation. Nevertheless, a recent body of data suggests that TNFα may also exert anti-inflammatory effects, which may be mediated in part via Tregs. TNFα binds to the TNF receptor 2 expressed preferentially at the Treg surface, thereby activating and promoting the development of Tregs. Data from patients with RA and more recent evidence obtained in the absence of disease are consistent with a paradoxical effect of TNFα on Tregs. TNFα may have different effects on naturally occurring Tregs and induced Tregs. Copyright Â
© 2011. Published by Elsevier SAS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22209316     DOI: 10.1016/j.jbspin.2011.09.017

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  14 in total

1.  In vitro TNF blockade enhances ex vivo expansion of regulatory T cells in patients with immune thrombocytopenia.

Authors:  Hui Zhong; James Bussel; Karina Yazdanbakhsh
Journal:  Br J Haematol       Date:  2014-09-24       Impact factor: 6.998

Review 2.  Arthritis models: usefulness and interpretation.

Authors:  Natacha Bessis; Patrice Decker; Eric Assier; Luca Semerano; Marie-Christophe Boissier
Journal:  Semin Immunopathol       Date:  2017-03-27       Impact factor: 9.623

3.  The Physiological Role of Tumor Necrosis Factor in Human Immunity and Its Potential Implications in Spinal Manipulative Therapy: A Narrative Literature Review.

Authors:  Liang Zhang; Chao Hua Yao
Journal:  J Chiropr Med       Date:  2016-05-26

4.  Porphyromonas gingivalis lipopolysaccharide activates canonical Wnt/β-catenin and p38 MAPK signalling in stem cells from the apical papilla.

Authors:  Jia Wang; Jiewen Dai; Bin Liu; Shensheng Gu; Lan Cheng; Jingping Liang
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

5.  Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation.

Authors:  Brendon J Coventry; Martin L Ashdown
Journal:  Cancer Manag Res       Date:  2012-05-28       Impact factor: 3.989

Review 6.  Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo.

Authors:  K C Webb; R Tung; L S Winterfield; A B Gottlieb; J M Eby; S W Henning; I C Le Poole
Journal:  Br J Dermatol       Date:  2015-08-25       Impact factor: 9.302

7.  Persistent p55TNFR expression impairs T cell responses during chronic tuberculosis and promotes reactivation.

Authors:  Ivy M Dambuza; Roanne Keeton; Nai-Jen Hsu; Nasiema Allie; Valérie F J Quesniaux; Bernhard Ryffel; Muazzam Jacobs
Journal:  Sci Rep       Date:  2016-12-20       Impact factor: 4.379

Review 8.  Classical and Paradoxical Effects of TNF-α on Bone Homeostasis.

Authors:  Bilal Osta; Giulia Benedetti; Pierre Miossec
Journal:  Front Immunol       Date:  2014-02-13       Impact factor: 7.561

9.  Homogeneous expansion of human T-regulatory cells via tumor necrosis factor receptor 2.

Authors:  Yoshiaki Okubo; Toshiyuki Mera; Limei Wang; Denise L Faustman
Journal:  Sci Rep       Date:  2013-11-06       Impact factor: 4.379

10.  CD4+FOXP3+ T Cells in Rheumatoid Arthritis Bone Marrow Are Partially Impaired.

Authors:  Magdalena Massalska; Anna Radzikowska; Ewa Kuca-Warnawin; Magdalena Plebanczyk; Monika Prochorec-Sobieszek; Urszula Skalska; Weronika Kurowska; Pawel Maldyk; Ewa Kontny; Hans-Jürgen Gober; Wlodzimierz Maslinski
Journal:  Cells       Date:  2020-02-26       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.